Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance).

Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). J Clin Oncol. 2017 Jul 01; 35(19):2184-2192.

View in: PubMed

subject areas

Antineoplastic Combined Chemotherapy Protocols
Carboplatin
Carcinoma, Small Cell
Celecoxib
Cyclooxygenase 2
Cyclooxygenase 2 Inhibitors
Dinoprostone
Disease-Free Survival
Double-Blind Method
Female
Humans
Lung Neoplasms
Male
Middle Aged
Neoplasm Staging
Pemetrexed
Survival Rate

authors with profiles

Everett E. Vokes
Olwen Hahn